#COVID19 | Bharat Biotech completes clinical development for phase III trials & booster doses for BBV154 intranasal covid vaccine. Bharat Biotech International LTd, announces that BBV154 has proven to be safe, well-tolerated & immunogenic in subjects in controlled clinical trials pic.twitter.com/UIfd1BhBhd— ANI (@ANI) August 15, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


